Changchun High-Tech Industry (Group) Co., Ltd. (SHE:000661)
China · Delayed Price · Currency is CNY | Market Cap | 36.27B -6.4% |
| Revenue (ttm) | 12.88B -9.7% |
| Net Income | 959.05M -74.1% |
| EPS | 2.39 -73.6% |
| Shares Out | 402.92M |
| PE Ratio | 37.71 |
| Forward PE | 16.50 |
| Dividend | 2.60 (2.71%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 2,499,502 |
| Average Volume | 8,469,215 |
| Open | 98.20 |
| Previous Close | 90.01 |
| Day's Range | 90.10 - 98.20 |
| 52-Week Range | 83.00 - 141.77 |
| Beta | 0.55 |
| RSI | 34.37 |
| Earnings Date | Mar 12, 2026 |
About SHE:000661
Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers genetic engineering, biological vaccines, antibody drugs, chemical drugs, and modern Chinese medicine. It also develops real estate properties. The company was founded in 1993 and is based in Changchun, China. [Read more]
Financial Performance
In 2024, SHE:000661's revenue was 13.47 billion, a decrease of -7.55% compared to the previous year's 14.57 billion. Earnings were 2.58 billion, a decrease of -43.01%.
Financial StatementsNews
Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion
A Chinese biopharmaceutical firm has sealed a global licensing deal valued at up to US$1.44 billion, the second in a week, as a wave of cross-border tie-ups shows no sign of abating despite headwinds ...